Cell Reactant:
Cytochrome P450 Reductase (CPR)
Syringe Reactant:
BDBM11942
Meas. Tech.:
Isothermal Titration Calorimetry
Entry Date.:
11/07/06
ΔG°:
-39.292±n/a (kJ/mole)
pH:
7±n/a
Log10Kb:
6.1
Temperature:
298.15±n/a (K)
ΔHobs :
-79.42±8.36 (kJ/mole)
Corrected for ΔHioniz:
not known
ΔCp :
-0.9196±n/a (kJ/mole)
Stoich. Param.:
1
ΔS° :
-0.1318±n/a (kJ/mole-K)
Citation
 Hoffman, JMGrunau, ASmith, AMPaine, MJRooney, CSLadbury, JEFisher, TEGutierrez, AWai, JSThomas, CMBamberger, DLBarnes, JLWilliams, TMJones, JH Global effects of the energetics of coenzyme binding: NADPH controls the protein interaction properties of human cytochrome P450 reductase. Biochemistry 45:1421-34 (2006) [PubMed]  Article
Cell React
Source:
Human fibroblast CPR (lacking the N-terminal membrane-anchoring region) and the functional FAD-binding domain were expressed in Escherichia coli BL21 (DE3).
Prep. Method:
The recombinant His-tagged proteins were purified to homogeneity by nickel-agarose chromatography. The notable exception is the omission of the 2,5-ADP affinity resin step to avoid the unusual biphasic binding isotherms during ITC experiment.
Name:
NADPH--cytochrome P450 reductase
Synonyms:
CYPOR | Cytochrome P450 Reductase (CPR) | NADPH--cytochrome P450 reductase | NCPR_HUMAN | P450R | POR
Type:
Enzyme
Mol. Mass.:
76675.22
Organism:
Homo sapiens (Human)
Description:
P16435
Residue:
677
Sequence:
MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWS
  
Syringe React
Source:
For H4NADP synthesis, High-purity hydrogen (99.995%) was supplied by BOC (Surrey, U.K.). Palladium (10% on activated charcoal) was purchased from ACROS Organics.
Prep. Method:
H4NADP was obtained by palladium-catalyzed hydrogenation of NADP(H).
Name:
BDBM11942
Synonyms:
1,4,5,6-tetrahydro-NADP | H4NADP
Type:
Nucleoside or nucleotide
Emp. Form.:
C21H32N7O17P3
Mol. Mass.:
747.4368
SMILES:
NC(=O)C1=CN(CCC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |r,t:3|
Structure:
Search PDB for entries with ligand similarity: